Startup profile for Aevius: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Aevius funding, valuation and investors

Mass General Brigham spinout building longitudinal patient-data foundation models for health systems, payers and life-sciences companies.

Verified company research · funding, investors and latest developments

Keep track of Aevius

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Financing (series undisclosed by issuer)

$22M · November 17, 2026

Latest known valuation

Undisclosed

Financing (series undisclosed by issuer) · November 17, 2026

Total disclosed equity funding

$22M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

Stage not recorded · Boston, Massachusetts, United States

Investors in latest funding

Lead: Insight Partners

Sources: latest funding · businesswire.com Last verified: 2026-11-19

Overview

Aevius Labs is a Boston Mass General Brigham spinout founded by Rowland Pettit (CEO), Ming Yang/Max Lu (CTO), Faisal Mahmood and Long Phi Le, all of whom helped build Modella AI before its acquisition by AstraZeneca. The previous acquisition's consideration is undisclosed. Aevius announced $22M of financing led by Insight Partners on Nov 17 2026; the issuer did not identify a series, valuation or exact legal closing date.

The new company proposes foundation models unifying structured medical records, text, imaging and other specialty modalities into a refreshable longitudinal representation of patients for research, care planning, cohort studies and payer analysis. This is not proof of regulatory approval, clinically validated prediction, broad deployment or revenue.

Pricing, customers, prospective validation, fairness and independently measured benefit remain undisclosed.

Why Aevius is interesting

An Insight Partners-led $22M company financing announced Nov 17 2026 addresses multimodal patient data, but its original issuer release does not identify a round series, valuation, clinical-validation study or paying customers.

Product & use cases

Illustrative health-system research deployment, not hands-on testing: 1. Confirm patient-data permissions, secure deployment and appropriate uses. 2. Normalize consented lab results, notes, images and longitudinal records with identifiers. 3. Aevius aims to construct updatable patient-history representations from those inputs. 4. Authorized analysts could ask cohort, risk and trajectory questions using those representations. 5. Independently test outputs on separate hospital cohorts, and put clinicians/privacy teams in the approval loop before any clinical use. The company has not published a production integration tutorial, commercial tariff, regulated-diagnostic approval or external-validation evidence.

  • Hospital analytics team seeks cohorts with comparable longitudinal clinical characteristics for retrospective studies.
  • Life-sciences sponsor examines patient trajectories or candidate biomarkers for trial design, with independent validation.
  • Payer population-health unit tests risk stratification, including bias, calibration and privacy safeguards.

Key facts

  • Company-issued Nov 17 2026: $22M funding led by Insight Partners, formal round series not issuer-confirmed.
  • Mass General Brigham spinout; founders previously built Modella AI, acquired by AstraZeneca for an undisclosed amount.
  • A proposed reusable patient representation across time, notes, imaging and medical records, not an approved diagnostic.
  • No external predictive benchmarks, deployed customer list, clinical endpoint validation, pricing or audited revenue provided.

Funding history (newest first)

Financing (series undisclosed by issuer)

2026-11-17 $22M Valuation: Undisclosed

Source: Read source · businesswire.com

Investors in our directory

Funds linked from Aevius's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

Edge: Reusing one patient representation across many downstream analytics tasks could reduce repetitive data joining, but the economic and clinical advantage is currently unproven.

Prospective clinical improvement cannot be inferred from patient representations. Hospital-to-hospital generalization, multimodal missingness, bias, consent, deidentification, model drift and explainability need evaluation. The issuer supplies no standardized benchmark or clinical approval, and company partnership invitations do not establish paid deployments. No source-backed evidence currently establishes superiority over Dyania, Owkin, Tempus or conventional clinical analytics.

  • Dyania Health direct

    Clinical text and medical-record review for research and operations.

  • Owkin direct

    Multimodal biomedical AI and research data networks.

  • Tempus AI alternative

    Molecular and clinical precision-medicine data tools.

  • Carta Healthcare alternative

    Registry abstraction and trial-identification workflows.

  • Health-system FHIR/data-warehouse analytics alternative

    In-house data preparation and validated task-specific models.

Market / IPO context

Editorial / static context — not a live quote.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.